Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
VAXIL BIO Aktie jetzt für 0€ handeln | |||||
15.05. | Vaxil Bio Ltd (2): Vaxil Bio resuming at the open | 4 | Stockwatch | ||
14.05. | Vaxil Bio Ltd (1): Vaxil Bio 1:50 rollback | 2 | Stockwatch | ||
06.05. | Vaxil Bio Ltd: Vaxil Bio plans 1:50 rollback | 1 | Stockwatch | ||
06.05. | Vaxil Bio Ltd.: Share Consolidation | 209 | GlobeNewswire (Europe) | Not for distribution by US newswire or in United States TORONTO, May 06, 2025 (GLOBE NEWSWIRE) -- VAXIL BIO LTD. ("Vaxil" or the "Company") (TSX VENTURE: VXL), is pleased to make the following updates... ► Artikel lesen | |
04.04. | Vaxil Bio Ltd: Vaxil Bio to close Israeli subsidiaries | 2 | Stockwatch | ||
03.04. | Vaxil Bio Ltd.: Vaxil: Management and Operational Update | 105 | GlobeNewswire (Europe) | Not for distribution by US newswire or in United States NESS-ZIONA, Israel, April 03, 2025 (GLOBE NEWSWIRE) -- VAXIL BIO LTD. ("Vaxil" or the "Company") (TSX VENTURE: VXL), is pleased to make the... ► Artikel lesen | |
01.04. | Vaxil Bio Ltd: Vaxil shareholders pass all resolutions at AGM | 1 | Stockwatch | ||
31.03. | Vaxil Bio Ltd.: VAXIL's Annual and Special Shareholders Meeting | 1 | GlobeNewswire (USA) | ||
16.01. | Vaxil Bio Ltd.: Vaxil Bio Proposed Reverse Takeover With Green Date Terminated | 142 | GlobeNewswire (Europe) | Not for distribution to United States newswire services or for release publication, distribution or dissemination directly, or indirectly, in whole or in part, in or into the United States NESS-ZIONA... ► Artikel lesen | |
21.08.24 | Vaxil Bio Ltd.: Vaxil Bio Enters Into Definitive Agreement With Green Data Centers for Reverse Take Over | 221 | GlobeNewswire (Europe) | Not for distribution to United States newswire services or for release, publication, distribution or dissemination directly, or indirectly, in whole or in part, in or into the United States. Any failure... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
MODERNA | 29,245 | +1,12 % | Aktie von Moderna heute am Aktienmarkt gefragt (28,74 €) | An der US-amerikanischen Börse notiert der Anteilsschein von Moderna derzeit etwas fester. Zuletzt zahlten Investoren für das Papier 28,74 Euro. Die Aktie von Moderna verzeichnet zur Stunde einen Wertanstieg... ► Artikel lesen | |
EVOTEC | 7,114 | +4,43 % | EQS-Adhoc: Evotec SE: Evotec passt Umsatzprognose an und bestätigt Gewinnprognose | EQS-Ad-hoc: Evotec SE / Schlagwort(e): Prognoseänderung
Evotec SE passt Umsatzprognose an und bestätigt Gewinnprognose
21.07.2025 / 11:25 CET/CEST
Veröffentlichung einer Insiderinformation... ► Artikel lesen | |
RECURSION PHARMACEUTICALS | 6,255 | 0,00 % | Can Recent Pipeline Expansion Efforts Offset RXRX's Earlier Losses? | ||
IMMUNOVANT | 18,320 | 0,00 % | Immunovant Inc.: Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2025 | Immunovant's new management team is focused on rapid clinical execution for the six announced indications for IMVT-1402, including a second potentially registrational study in Graves' disease (GD)... ► Artikel lesen | |
QIAGEN | 43,510 | +1,83 % | BERENBERG stuft QIAGEN NV auf 'Buy' | HAMBURG (dpa-AFX Analyser) - Die Privatbank Berenberg hat das Kursziel für Qiagen von 48 auf 50 Euro angehoben und die Einstufung auf "Buy" belassen. Analyst Harry Gillis "diagnostiziert" eine defensive... ► Artikel lesen | |
EDGEWISE THERAPEUTICS | 14,630 | 0,00 % | Edgewise Therapeutics Reports Positive Results on Sevasemten Program for Becker and Duchenne Muscular Dystrophies | - New open label data in Becker demonstrated sustained disease stabilization up to three years, reinforcing prior clinical findings -- Ongoing pivotal trial and FDA Type C meeting provide... ► Artikel lesen | |
JANUX THERAPEUTICS | 25,970 | 0,00 % | Raymond James startet Coverage für Janux Therapeutics mit "Outperform"-Rating | ||
VERVE THERAPEUTICS | 11,130 | 0,00 % | Lilly completes tender offer for Verve Therapeutics shares | ||
VIR BIOTECHNOLOGY | 5,760 | 0,00 % | Vir Biotechnology, Inc. - 8-K, Current Report | ||
SANA BIOTECHNOLOGY | 5,125 | 0,00 % | Citi Maintained a Buy Rating on Sana Biotechnology (SANA) | ||
BEAM THERAPEUTICS | 20,960 | 0,00 % | Beam Therapeutics Announces New Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 Supporting Differentiated Profile in Sickle Cell Disease (SCD) at European Hematology Association (EHA) 2025 Congress | Updated Data from 17 Patients Consistent with Previously Presented Data; All Patients Treated with BEAM-101 Achieved Hemoglobin F (HbF) Induction of >60%, Hemoglobin S (HbS) Reduction to Patients... ► Artikel lesen | |
SUMMIT THERAPEUTICS | 27,545 | 0,00 % | Summit Therapeutics vor Mega-Deal: Aktie +15% | Papiere von Summit Therapeutics legen heute in der Spitze um +15% zu. Vorausgegangen ist ein Bloomberg-Bericht um einen bevorstehenden Mega-Deals mit dem Pharmakonzern AstraZeneca. Laut Bloomberg News... ► Artikel lesen | |
ARCTURUS THERAPEUTICS | 14,950 | 0,00 % | EU Grants Marketing Authorization For KOSTAIVE To CSL And Arcturus Therapeutics | CANBERA (dpa-AFX) - Biotechnology firm CSL Ltd. (CSL.AX, CMXHF.PK) and sa-mRNA pioneer Arcturus Therapeutics Ltd. (ARCT) announced Friday that the European Commission has granted marketing authorization... ► Artikel lesen | |
ADMA BIOLOGICS | 17,310 | 0,00 % | ADMA Biologics, Inc.: ADMA Biologics Announces First Quarter 2025 Financial Results and Provides Business Update | 1Q 2025 Total Revenue of $114.8 Million (Adjusted Total Revenue(1) of $118.6 Million), a 40% YoY Increase 1Q 2025 GAAP Net Income of $26.9 Million, a 51% YoY Increase 1Q 2025 Adjusted EBITDA(2) of... ► Artikel lesen | |
UPSTREAM BIO | 13,350 | 0,00 % | Upstream Bio Announces First Patient Dosed in Phase 2 Clinical Trial of Verekitug in Chronic Obstructive Pulmonary Disease (COPD) | - Global Phase 2 clinical trial, VENTURE, to evaluate the efficacy and safety of verekitug administered every 12 or 24 weeks in moderate-to-severe COPD - - Broadens global development program for... ► Artikel lesen |